Twist Bioscience Corporation (TWST) Tops Q1 EPS by 2c, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. ADYYF
9. TPR
10. DGNX

Go back to Twist Bioscience Corporation (TWST) Tops Q1 EPS by 2c, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results

February 4, 2021 4:05 PM EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31, 2020.

We reported a strong quarter both for orders and revenue, building a solid foundation for fiscal 2021, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. We see early evidence that our investment in synbio products for our pharmaceutical and biotech customers is beginning to gain... More